You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 137 No. 4, April 2001 TABLE OF CONTENTS
  Archives
  •  Online Features
  Review
 This Article
 •Full text
 •PDF
 •Correction
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (7)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Rheumatology
 •Osteoporosis
 •Review
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic

Suggested Rationale for Prevention and Treatment of Glucocorticoid-Induced Bone Loss in Dermatologic Patients

Gil Yosipovitch, MD; Tan Suat Hoon, MD; Goh Chee Leok, MD

Arch Dermatol. 2001;137:477-481.

Glucocorticoid-induced bone loss is the most predictable and debilitating complication of prolonged administration of systemic corticosteroids. It has been shown that patients treated with glucocorticoids have an increased risk of osteoporotic fractures, resulting in marked morbidity, particularly in elderly individuals. Studies on the effect of glucocorticoids on bone density and the efficacy of treatment regimens (namely, bisphosphonates and calcitonin) for preventing bone loss have been mainly on patients with asthma and rheumatologic diseases. However, no long-term studies have been done on the impact of prolonged corticosteroid treatment in dermatologic patients. The purpose of this review is to raise awareness about osteoporosis and new preventive measures among the dermatologists treating patients with glucocorticoids at high doses and for long periods. We summarize the assessment methods used to evaluate this condition, examine the results of clinical trials of drugs, and suggest a practical approach to managing corticosteroid osteoporosis in dermatologic patients based on data collected from published articles.


From the National Skin Cancer Center, Singapore (Drs Yosipovitch and Leok). Dr Hoon is a consultant in Singapore.


RELATED ARTICLES

Time to End Steroid-Induced Fractures
Ian R. Reid
Arch Dermatol. 2001;137(4):493-494.
EXTRACT | FULL TEXT  

Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 2001;137(4):520.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cross-sectional Study of Bisphosphonate Use in Dermatology Patients Receiving Long-term Oral Corticosteroid Therapy
Liu et al.
Arch Dermatol 2006;142:37-41.
ABSTRACT | FULL TEXT  

Glucocorticoid-Induced Bone Loss in Dermatologic Patients: An Update
Summey and Yosipovitch
Arch Dermatol 2006;142:82-90.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.